Abstract
Hypertrophic cardiomyopathy (HCM) is a complex and common genetic cardiac disease and it is a primary disease of the cardiac muscle that typically displays a marked and diffuse pattern of ventricular wall thickening (1). A variant apical form of HCM is characterized by wall thickening confined to the ventricular apex, with a typical ‘ace of spade’ configuration (2, 3). Although apical hypertrophic cardiomyINTRODUCTION �Received; January 12, 2014�Revised; February 14, 2014 �Accepted; March 5, 2014 Corresponding author : Eun Ju Chun, M.D., Ph.D. Divison of Cardiovascular Imaging, Department of Radiology, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Korea. Tel. 82-31-787-7618, Fax. 82-31-787-4011 E-mail : drejchun@hanmail.net This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. First-pass Stress Perfusion MR Imaging Findings of Apical Hypertrophic Cardiomyopathy: with Relation to LV Wall Thickness and Late Gadolinium-enhancement
Highlights
To evaluate the prevalence and pattern of perfusion defect (PD) on first-pass stress perfusion MR imaging in relation with the degree of left ventricular hypertrophy (LVH) and late gadolinium-enhancement (LGE) in patients with apical hypertrophic cardiomyopathy (APH)
Cardiac MR imaging with first-pass stress perfusion, cine, and LGE sequence was performed in 26 patients with APH from January 2008 to December 2012
We analyzed a total of 416 segments for LV wall thickness on end-diastolic phase of cine images, and evaluated the
Summary
To evaluate the prevalence and pattern of perfusion defect (PD) on first-pass stress perfusion MR imaging in relation with the degree of left ventricular hypertrophy (LVH) and late gadolinium-enhancement (LGE) in patients with apical hypertrophic cardiomyopathy (APH)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.